Researchers conducted a retrospective study to determine if the Trunk Impairment Scale (TIS), designed for stroke patients, effectively measures trunk impairment in Parkinson’s disease (PD).
They included successive inpatient cases of PD with executed correlation analysis to establish the association between TIS assessment and various factors like balance functions, lower extremity muscle strength, and walking ability. Factor analysis was implemented to observe the differences in background factors of TIS compared to balance function, lower limb muscle strength, and walking ability.
The results showed correlations between TIS and various assessments in 471 Parkinson’s disease (PD) patients: Mini-Balance Evaluation Systems Test (r=0.67), Barthel Index (r=0.57), general lower limb extension torque (r=0.51), two-minute walk test (r=0.54), Hoehn and Yahr stage (r=-0.61), and Movement Disorder Society Unified PD Rating Scale part III total points (r=-0.59). The factor analysis indicated TIS items were categorized into three factors: an abdominal muscles and righting reflex component, a perception and verticality component, and a rotational component. This differentiation sets it apart from other scales with clinical assessment items.
Investigators concluded that TIS was a promising tool for understanding trunk dysfunction and its contributions to daily life, gait, and balance in patients with PD.
Source: frontiersin.org/articles/10.3389/fneur.2023.1303215/full
Originally Published By Physician’s Weekly. Reused by Medicom Medical Publishers with permission.
©2024 Physician’s Weekly. All rights reserved. No works may be reproduced without expressed written consent from Physician’s Weekly. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by Physician’s Weekly.
Posted on
Previous Article
« Interview: Are we on a path towards a cure for Parkinson’s? Next Article
Examining Biomarkers in Extracellular Vesicles Enriched in the Central Nervous System for Parkinsonian Disorders »
« Interview: Are we on a path towards a cure for Parkinson’s? Next Article
Examining Biomarkers in Extracellular Vesicles Enriched in the Central Nervous System for Parkinsonian Disorders »
Related Articles
December 9, 2021
Eculizumab, satralizumab, or inebilizumab for NMOSD?
August 18, 2021
Inability to recognise disgust as first cognitive symptom of ALS
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy